Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity Across 28-8, 22C3, and SP263 Assays.
Klempner SJ, Cowden ES, Cytryn SL, Fassan M, Kawakami H, Shimada H, Tang LH, Wagner DC, Yatabe Y, Savchenko A, Salcius J, Johng D, Chen J, Montenegro G, Moehler M. Klempner SJ, et al. Among authors: cytryn sl. JCO Precis Oncol. 2024 Jun;8:e2400230. doi: 10.1200/PO.24.00230. JCO Precis Oncol. 2024. PMID: 38822761
18F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer.
Cytryn SL, Pandit-Taskar N, Lumish MA, Maron SB, Gu P, Ku GY, Chou JF, Capanu M, Antoine A, Loegel D, Feder L, Philemond S, Lyashchenko SK, Lewis JS, Paroder V, Srivastava A, Tang LH, Schoder H, Janjigian YY. Cytryn SL, et al. J Nucl Med. 2024 May 1;65(5):722-727. doi: 10.2967/jnumed.123.267186. J Nucl Med. 2024. PMID: 38514081
Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma.
Fick CN, Dunne EG, Sihag S, Molena D, Cytryn SL, Janjigian YY, Wu AJ, Worrell SG, Hofstetter WL, Jones DR, Gray KD. Fick CN, et al. Among authors: cytryn sl. Ann Thorac Surg. 2024 Feb 24:S0003-4975(24)00125-5. doi: 10.1016/j.athoracsur.2024.02.021. Online ahead of print. Ann Thorac Surg. 2024. PMID: 38408631 Review.
First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial.
Cytryn SL, Moy RH, Cowzer D, Shah RH, Chou JF, Joshi SS, Ku GY, Maron SB, Desai A, Yang J, Sugarman R, Rao D, Goldberg Z, Charalambous C, Lapshina M, Antoine A, Socolow F, Trivedi N, Capanu M, Gerdes H, Schattner MA, Simmons M, Lacouture ME, Paroder V, Tang LH, Shia J, Ilson DH, Solit DB, Berger MF, Janjigian YY. Cytryn SL, et al. Lancet Oncol. 2023 Oct;24(10):1073-1082. doi: 10.1016/S1470-2045(23)00358-3. Epub 2023 Sep 1. Lancet Oncol. 2023. PMID: 37666264 Clinical Trial.